➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Colorcon
Boehringer Ingelheim
Mallinckrodt
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 8,871,450

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,871,450
Title:Biomarker for colorectal cancer
Abstract: The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.
Inventor(s): Hacker; Ulrich (Cologne, DE), Goede; Valentin (Cologne, DE), Coutelle; Oliver (Cologne, DE)
Assignee: Universitat zu Koln (Cologne, DE)
Application Number:13/390,532
Patent Claims:see list of patent claims

Details for Patent 8,871,450

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Universitat zu Koln (Cologne, DE) 2029-09-07 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Universitat zu Koln (Cologne, DE) 2029-09-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Merck
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.